Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020
Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020'; Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.
The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Migraine, Trigeminal Neuralgia (Tic Douloureux), Resistant Hypertension and Tension -Type Headache.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020'; Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.
The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Migraine, Trigeminal Neuralgia (Tic Douloureux), Resistant Hypertension and Tension -Type Headache.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
Adepthera LLC
Allergan Plc
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Sosei Heptares
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BHV-3500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
Dec 18, 2019: Biohaven reports positive data from migraine trial of vazegepant
Oct 31, 2019: Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT Technology
Sep 27, 2019: NICE rejects Novartis’ migraine drug Aimovig over data concerns
Sep 12, 2019: Biohaven closes enrolment in vazegepant’s Phase II/III study
Sep 09, 2019: Biohaven presents data demonstrating reduction in Migraine-related disability and improvement in patient reported outcomes after oral treatment with Rimegepant at The International Headache Conference Late Breaking Session
Aug 08, 2019: Biohaven completes patient enrolment in rimegepant trial for migraine
Jul 15, 2019: Biohaven's positive phase 3 trial of Rimegepant Zydis orally dissolving tablet for acute treatment of migraine published in The Lancet
Jul 11, 2019: Rimegepant shows positive result as migraine drug in Phase III trial
Jul 11, 2019: Biohaven showcases positive data on Rimegepant, oral CGRP receptor antagonist, with 16 presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting demonstrating efficacy in multiple patient types and long-term safety
Jul 10, 2019: New antibody treatment provides little relief for high-frequency migraine patients
Jul 09, 2019: Allergan provides update on atogepant at the 2019 American Headache Society Annual Meeting
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
Jul 02, 2019: Novartis’ Aimovig yields positive data in open label period
Jul 01, 2019: Novartis data show Aimovig cuts acute migraine medication days by half in patients who failed prior preventive therapies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
Adepthera LLC
Allergan Plc
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Sosei Heptares
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BHV-3500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
Dec 18, 2019: Biohaven reports positive data from migraine trial of vazegepant
Oct 31, 2019: Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT Technology
Sep 27, 2019: NICE rejects Novartis’ migraine drug Aimovig over data concerns
Sep 12, 2019: Biohaven closes enrolment in vazegepant’s Phase II/III study
Sep 09, 2019: Biohaven presents data demonstrating reduction in Migraine-related disability and improvement in patient reported outcomes after oral treatment with Rimegepant at The International Headache Conference Late Breaking Session
Aug 08, 2019: Biohaven completes patient enrolment in rimegepant trial for migraine
Jul 15, 2019: Biohaven's positive phase 3 trial of Rimegepant Zydis orally dissolving tablet for acute treatment of migraine published in The Lancet
Jul 11, 2019: Rimegepant shows positive result as migraine drug in Phase III trial
Jul 11, 2019: Biohaven showcases positive data on Rimegepant, oral CGRP receptor antagonist, with 16 presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting demonstrating efficacy in multiple patient types and long-term safety
Jul 10, 2019: New antibody treatment provides little relief for high-frequency migraine patients
Jul 09, 2019: Allergan provides update on atogepant at the 2019 American Headache Society Annual Meeting
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
Jul 02, 2019: Novartis’ Aimovig yields positive data in open label period
Jul 01, 2019: Novartis data show Aimovig cuts acute migraine medication days by half in patients who failed prior preventive therapies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adepthera LLC, H1 2020
Pipeline by Allergan Plc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
Pipeline by Sosei Heptares, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adepthera LLC, H1 2020
Pipeline by Allergan Plc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
Pipeline by Sosei Heptares, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Adepthera LLC
Allergan Plc
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Sosei Heptares
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Adepthera LLC
Allergan Plc
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Sosei Heptares
